Company Of The Day: Pfizer

November 2nd, 2022 by Trefis Team
+46.94%
Upside
38.36
Market
56.37
Trefis
PFE: Pfizer logo
PFE
Pfizer

What?

Pfizer (NYSE:PFE) posted a stronger-than-expected set of Q3 2022 results. Although revenue declined by about 6% versus last year to $22.6 billion, it came in ahead of estimates. Adjusted earnings stood at $1.78 per share, up 40% versus last year.

Why?

Relevant Articles
  1. Will Pfizer Stock See Higher Levels Post Q1 Earnings?
  2. Is Pfizer Stock Undervalued At $40?
  3. This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
  4. What To Expect From Pfizer’s Q4?
  5. Is Pfizer Stock A Better Pick Over This Pharmaceuticals Bellwether?
  6. Should You Buy Pfizer Stock Ahead of Its Q3 Results?

While sales were weighed down by lower Covid-19 vaccine sales, this was partly offset by strong sales of Pfizer’s antiviral drug Paxlovid as well as Prevnar and Eliquis.

So What?

PFE stock was up by about 3% in Tuesday’s trading.

See Our Complete Analysis For Pfizer

What if you’re looking for a more balanced portfolio instead? Our high-quality portfolio and multi-strategy portfolio have beaten the market consistently since the end of 2016.

Returns Nov 2022
MTD [1]		 2022
YTD [1]		 2017-22
Total [2]
 PFE Return 3% -19% 48%
 S&P 500 Return 0% -19% 72%
 Trefis Multi-Strategy Portfolio 0% -22% 208%

[1] Month-to-date and year-to-date as of 11/2/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates